ONCO

Onconetix, Inc. (ONCO) - 10-K Summary for Fiscal Year Ended December 31, 2025

Business Context and Reporting Period

Company: Onconetix, Inc.
Reporting Period: Fiscal Year Ended December 31, 2025
Business Model: Commercial-stage biotechnology company focused on men's health and oncology. The company's primary asset is Proclarix, an in vitro diagnostic test for prostate cancer approved in the European Union (EU) under the In Vitro Diagnostic Regulation (IVDR). The company abandoned the commercialization of its other asset, ENTADFI (a BPH treatment), in 2024 due to cash constraints and resource allocation.
Key Developments:

• Realbotix Transaction: On February 11, 2026, the company entered into a Share Exchange Agreement to acquire Realbotix, LLC, a technology company. The transaction is subject to closing conditions, including a minimum net cash requirement of $12.5 million and stockholder approval.
• Financing: Completed Series D (September 2025) and Series E (October 2025) PIPE financings, raising approximately $15.5 million in aggregate gross proceeds to extend its cash runway.
• Reverse Stock Split: Effectuated a 1-for-85 reverse stock split on June 13, 2025, to regain compliance with Nasdaq listing requirements.

Key Financial Metrics

Note: Revenue in 2025 included $0.59 million in license revenue from Immunovia and $0.23 million in product sales. The significant reduction in net loss compared to 2024 was driven by the absence of large impairment charges recorded in the prior year.

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased by 67.7% to $0.82 million, primarily due to the completion of a non-recurring development services contract with Immunovia in 2024 ($2.28 million) which did not recur in 2025. This was partially offset by new license revenue from Immunovia in 2025.
• Impairment Charges:
  • 2025: Recorded a goodwill impairment of $11.5 million. No impairment was recorded for ENTADFI assets or intangibles as they were fully impaired in 2024.
  • 2024: Recorded significant impairments totaling $46.2 million, including $32.3 million for goodwill, $10.3 million for intangibles, and $3.5 million for ENTADFI assets.
• Debt Settlement: In September 2025, the company settled approximately $8.8 million in debt obligations to Veru Inc. (related to the ENTADFI acquisition) through a combination of cash ($6.3 million) and equity (Series D Preferred Stock and Warrants). This resulted in a loss on extinguishment of notes payable of $5.38 million.
• Derivative Liabilities: Recognized significant fair value gains on warrant and derivative liabilities in 2025 ($14.9 million net gain) due to the reclassification of Series D and E warrants to equity following a waiver amendment in December 2025.

Guidance, Outlook, Risks, and Contingencies

Going Concern: The company has raised substantial doubt about its ability to continue as a going concern for one year from the date of issuance. While Series D and E financings provided near-term liquidity, the company continues to generate recurring net operating losses and has no committed sources of financing beyond its existing Equity Line of Credit (ELOC).

Outlook:

• Proclarix Commercialization: The company expects growing revenues from Proclarix sales in Europe in 2026. In the U.S., commercialization is dependent on LabCorp, which has exclusive rights. A new validation study (PRIME Study) with LabCorp is scheduled to begin in 2026.
• Realbotix Integration: Management anticipates the Realbotix transaction will provide a new revenue stream, though integration risks and potential dilution to existing shareholders are noted.

Key Risks:

• Liquidity: Insufficient cash to fund operations for one year without additional capital raises.
• Regulatory: Proclarix is not yet approved for sale in the U.S. as a Lab Developed Test (LDT) by CMS/state agencies, and FDA rules regarding LDTs are evolving.
• Concentration: 100% of development service revenue and 92% of product sales revenue in 2025 came from a single customer (Immunovia).
• Internal Controls: The company identified material weaknesses in internal controls over financial reporting, including inadequate segregation of duties and insufficient accounting resources.

Investor Verification Checklist

• Cash Runway: Verify the current cash balance (reported as ~$3.6 million as of March 11, 2026) against the burn rate to confirm the timeline for the next capital raise.
• Realbotix Closing Conditions: Monitor the status of the $12.5 million net cash condition and stockholder approval required to close the Realbotix acquisition.
• Proclarix U.S. Status: Confirm the progress of the PRIME Study with LabCorp and any regulatory updates regarding LDT enforcement discretion.
• Debt Obligations: Review the terms of the remaining ELOC facility and any new debt incurred for the D&O insurance policy (noted as $247k note payable in subsequent events).
• Internal Control Remediation: Assess the progress of the remediation plan for the identified material weaknesses in internal controls.